July 9, 2026 · Form 4 insider transaction
Ben-Elazar Pini bought 8,313 shares of Regentis Biomaterials Ltd. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
This option grant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026.; This option grant is fully vested as of this date.; To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee.